Dafang Zhang, MD
Orthopaedic Surgery · Boston, MANPI 1164860243
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $8,360 of the $9,555 with a category attached, or 87.5%. 7 manufacturers reported payments, led by Alnylam Pharmaceuticals Inc. at 57.1% of the total. Reporting peaked in 2020 at $3,000 and has fallen 96.7% since, to $100 in 2025.
Across 20 payments — averaging $477.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alnylam Pharmaceuticals Inc.$5K
- Akcea Therapeutics, Inc.$3K
- Trimed, Inc.$744
- Endo Pharmaceuticals Inc.$217
- Medical Device Business Services, Inc.$74
- Sonex Health, Inc.$41
- plus $27 from 1 others
Across 3 payments — averaging $100,662 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Akcea Therapeutics, Inc.$302K
What the payments were for
- Consulting fees$8,36087%
- Food & beverage$1,11212%
- Education$831%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alnylam Pharmaceuticals Inc. | 3 | $5,453 |
| Akcea Therapeutics, Inc. | 1 | $3,000 |
| Trimed, Inc. | 7 | $744 |
| Endo Pharmaceuticals Inc. | 3 | $217 |
| Medical Device Business Services, Inc. | 3 | $74 |
| Sonex Health, Inc. | 2 | $41 |
| Zimmer Biomet | 1 | $27 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ONPATTRO$5,360
- Tools - AFS$644
- XIAFLEX$125
How this compares
$9,555 in reported general payments places this provider in the 65th percentile of 542 orthopaedic surgery providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Meloxicam | 36 | $56 |
| Ibuprofen | 17 | $52 |
Paid to pharmacies, not to this prescriber.
Other orthopaedic surgery in Boston
- Paul TornettaBoston$16.3M
- Thomas ThornhillBoston$12M
- Andrew FreibergBoston$5.9M
- Jon WarnerBoston$5.4M
- Wolfgang FitzBoston$3.7M
- John KwonBoston$663K
- Christopher ChiodoBoston$539K
- Andrew WhiteBoston$438K
- Carl TalmoBoston$315K
- Michael KainBoston$171K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.